Athenex, Inc. (60) | Uncategorized (8)

Recent Contracts

Second Amended and Restated Co-Development Agreement between Baylor College of Medicine and Kuur Therapeutics Limited, dated October 12, 2021 (Filed With SEC on March 16, 2022)
Amended and Restated Co-Development Agreement between Baylor College of Medicine and Kuur Therapeutics Limited, dated February 28, 2020 (Filed With SEC on August 5, 2021)
Lock-Up Agreement between Athenex, Inc. and Touchstone Innovations Businesses LLP (IP Group), dated May 4, 2021 (Filed With SEC on May 5, 2021)
Lock-Up Agreement between Athenex, Inc. and each of the parties named therein, dated as of May 4, 2021 (Filed With SEC on May 5, 2021)
Description of Securities (Filed With SEC on March 2, 2020)
First Amendment to Agreement by and between M+W U.S., Inc. and Athenex, Inc., effective as of March 27, 2018 (Filed With SEC on May 9, 2019)
Second Amendment to Agreement by and between M+W U.S., Inc. and Athenex, Inc., effective as of October 1, 2018 (Filed With SEC on May 9, 2019)
Sublicense Agreement, dated as of December 30, 2018 by and among Chongqing Taihao Pharmaceutical Co. Ltd., Chongqing Jingdong Junzhuo Pharmaceutical Co., Ltd., and Athenex, Inc (Filed With SEC on January 3, 2019)